Follow-on biologics: data exclusivity and the balance between innovation and competition.
Legislation to create a regulatory pathway for follow-on biologics is currently being considered by the United States Congress. A critical issue in this respect is the period of data exclusivity for innovator companies before a follow-on competitor can rely in part on data obtained for an original biologic for an abbreviated approval. Given the nature of patents on biologics, the period of data exclusivity is anticipated to have a key role in determining how quickly follow-on competitors emerge, and consequently also on the time available for originator companies to recoup their investment. With this issue in mind, this article discusses factors influencing return on investment on biologic research and development. A break-even analysis for a representative portfolio of biologics provides support for a substantial data exclusivity period.
Grabowski
Henry
H
Department of Economics, CB 90097, Duke University, Durham, North Carolina 27708, USA. grabow@econ.duke.edu
D001709:Biotechnology / Q000191:economics* / Q000331:legislation & jurisprudence / Q000639:trends; D004059:Diffusion of Innovation; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence / Q000639:trends; D016568:Drugs, Generic / Q000191:economics / Q000592:standards; D004465:Economic Competition; D007880:Legislation, Drug; D040541:Marketing; D014481:United States; D014486:United States Food and Drug Administration
D016568:Drugs, Generic